Job type: Full-time, Permanent
Location: Oxford
Salary: Competitive salary
Right to work: You must have the right to work in the UK
Application deadline: 8th August 2025
Application submission: CV and cover letter via our website www.omass.com/working-here/
In the second quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.
We successfully placed executives for venture capital & private equity-backed firms, alongside large-cap, mid-cap, and public companies, filling critical roles across diverse disciplines worldwide.
CEO/ C-suite/ Board
About the Team
The Chemical Biology Services Team at the European Bioinformatics Institute (EMBL-EBI) is looking for a talented Scientist with a flair for data curation to be responsible for the quality of bioactivity and drug discovery data in the ChEMBL database.
Have you moved from the lab into management or leadership in recent months? Perhaps you’ve started line managing for the first time? or recently taken on a team you weren’t expecting to manage?
If so, you may be feeling excited and daunted in equal measure! And perhaps would value some time spent honing your management techniques and approaches so you get the best out of those who report to you.
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
Cambridge, UK, 22 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders1.
Pioneer Group and Science Creates today announce a new partnership that will support the next generation of science and technology ventures across the UK and Ireland.
The collaboration brings together two mission-led organisations committed to helping founders translate scientific discovery into commercial solutions to tackle some of the most pressing challenges in human and planetary health.
GenePORTER® Gold from Amsbio is a highly reproducible, lipid-based gene transfection reagent delivering exceptional efficiency across the widest range of cell lines. Utilizing proprietary Advanced Carrier Enhancement (ACE) technology - GenePORTER® Gold delivers outstanding transfection efficiency and transgene expression levels with minimal cytotoxicity.
Amsbio offers a wide range of highly pure, lyophilized exosome standards designed to support reproducibility and standardization in extracellular vesicle (EV) research.
Exosomes are small lipid nanoparticles actively secreted by exocytosis in most living cells. Regulating pleiotropic physiological and pathological functions – exosomes have been shown to play significant roles in diverse pathological conditions such as cancer, infectious and neurodegenerative diseases. Currently there is growing interest in exosomes as promising new tools for use such as biomarkers and therapeutics.
Two groundbreaking drug discovery projects, supported by Medicines Discovery Catapult (MDC), have secured over £1m in funding from Innovate UK's Launchpad Northern Ireland programme.
SignaCor Therapeutics and Klas Therapeutics, both based in Northern Ireland, have been awarded a share of funding from the Launchpad programme.
The funding provides a vital boost to the SMEs' research programmes, which focus on innovations to treat heart disease and skin cancer.
Join us for a relaxed Friday afternoon of science, pitches, and networking at the o2h chaitime portfolio pitch day – where early-stage biotech companies meet investors and strategic partners.